
|Articles|April 14, 2017
- Vol 34 No 4
- Volume 34
- Issue 4
Taking the Pulse
Author(s)Richard M. Berlin, MD
Introduce yourself, shake hands, sit down. Always sit down. Then ask for permission...
Advertisement
Introduce yourself,
shake hands, sit down.
Always sit down.
Then ask for permission.
Press the wrist’s flesh
with the same pressure
you placed on your chest
when you swore your oath.
Count the rate.
Close your eyes.
Appreciate the rhythm,
each rise and fall,
crescendo, pause,
flutter and thrill,
the flow, the stream,
a body entered
through 2 fingertips
with enough nerve
and sense to reveal
the secrets deep
in your patient’s heart.
Articles in this issue
over 9 years ago
Introduction: Deep Dives and Intellectual Jujitsuover 9 years ago
Assisted Outpatient Treatment Enters the Mainstreamover 9 years ago
Across the (Psychiatric) Universeover 9 years ago
Bizarro WorldAdvertisement
Related to this article

FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.

Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.

How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.

There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?

APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.

Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Relief Is Not Free: A Case Study of Athlete Cannabis Use
4
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
5


